PTC Therapeutics Inc
PTCT
NASDAQ
Biotechnology
$71.70
USD
-0.27 (-0.38%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $6.01B
Volume 564.3K
Revenue
$1.01B
TTM
-42.8%
YoY
Gross Margin
93%
TTM
-4.2%
YoY
Net Income
$-38.38M
TTM
-106.1%
YoY
Operating Cash Flow
$-30.50M
TTM
-104.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 178.9 | 211.0 | 164.7 | 272.6 | 360.5 |
YoY Growth | -4.2% | +7.2% | -22.7% | -76.8% | +101.5% |
Cost of Revenue | 11.4 | 15.8 | 7.0 | 28.0 | 19.9 |
Gross Profit | 167.5 | 195.2 | 157.7 | 244.5 | 340.6 |
Selling, General & Administrative | 85.3 | 84.0 | 96.9 | 86.2 | 80.6 |
Other Operating Expenses | 0.1 | 0.5 | -11.1 | 0.9 | 0.0 |
Total Operating Expenses | 202.4 | 192.2 | 228.3 | 199.6 | 191.6 |
Operating Income | -35.0 | 3.0 | -70.5 | 45.0 | 149.0 |
EBITDA | -27.3 | 14.6 | -67.9 | 61.3 | 164.9 |
Other Income / Expense | -5.7 | 6.5 | -13.3 | 1.6 | -3.0 |
Total Other Income / Expense | -36.1 | -26.1 | -68.5 | -47.4 | -51.4 |
Income Before Income Taxes | -71.1 | -23.1 | -139.1 | -2.5 | 97.5 |
Income Taxes | -6.2 | -39.0 | -4.1 | 0.3 | 14.0 |
Net Income | -64.8 | 15.9 | -135.0 | -2.8 | 83.5 |
Consolidated Net Income / Loss | -64.8 | 15.9 | -135.0 | -2.8 | 83.5 |
Net Income Attributable to Common Shareholders | -64.8 | 15.9 | -135.0 | -2.8 | 83.5 |
Basic EPS | -$0.83 | $0.20 | -$1.62 | -$0.03 | $1.01 |
Diluted EPS | -$0.83 | $0.20 | -$1.33 | -$0.03 | $0.92 |
Basic Shares Outstanding | 78.2M | 78.5M | 83.4M | 82.5M | 83.0M |
Diluted Shares Outstanding | 78.2M | 87.1M | 101.6M | 82.5M | 92.0M |